The EMIT® II Plus Amphetamines Assay is intended for the qualit ative and semiquantitative determination of amphetamines in human urine, at a cutoff value of 300 ng/mL, 500 ng/mL, or 1000 ng/mL. The SAMHSA initial test cutoff level is 500 ng/mL.
The EMIT® II Plus Amphetamines Assay is intended for the qualit ative and semiquantitative determination of amphetamines in human urine, at a cutoff value of 300 ng/mL, 500 ng/mL, or 1000 ng/mL. The SAMHSA initial test cutoff level is 500 ng/mL.
Amphetamine, dextroamphetamine, and methamphetamine are collectively referred to as amphetamines. Today, amphetamine is used as an aid in treating narcolepsy, some forms of depression, and Attention Deficit Hyperactivity Disorder (ADHD). Yet, due to its potential for abuse or addiction, other treatment methods are used more frequently.
Applications available for the Viva-Jr®, Viva-E®, V-Twin®, and AU® Series analyzers*
Assay Principle | Homogeneous Enzyme Multiplied Immonoassay (EMIT) |
Cut-off | 300 ng/mL, 500 ng/mL, and 1000 ng/mL |
Sample | Urine |
Reagent Stability | Unopened until expiration date. On-board instrument up to: 4 weeks |
Calibration Frequency | As indicated by control results |